The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Does current evidence support the use of MRD-guided treatment before transplant in patients with AML?

Sep 17, 2020

The virtual AML Hub Satellite Symposiumat the 46 thAnnual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) brought together an international panel of expertsto discuss how measurable residual disease (MRD) impacts outcome of stem cell transplantation in AML, now and in the future. Professor Adriano Venditti, University of Rome Tor Vergata, Rome, IT, presented the topic ‘Does current evidence support the use of MRD-guided treatment before transplant in patients with AML?’

Apart from being a predictor of outcomes in AML, MRD assessment prior to stem cell transplantation is emerging as an important indicator for therapeutic decision making. Professor Adriano Venditti discusses the results of ongoing clinical trials using an MRD-guided treatment approach and highlights the benefits of stem cell transplantation even in MRD-positive patients, especially those in a specific risk group.

The first AML Hub Satellite Symposium: Watch here!

Welcome to the AML Hub Satellite Symposium.

Please take a moment to complete the survey and answer the following question to help us gauge your current understanding of the use of MRD-guided treatment before transplant in patients with AML.